Abstract
Secondary central nervous system (CNS) involvement in Mantle cell lymphoma has poor outcomes, with limited data for efficacy of CAR-T therapy. This study reports encouraging response with reasonable safety profile, but risk of CNS relapse remains high in such patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have